AstraZeneca PLC - Capital Expenditures

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Capital-Expenditures" stands at 5.57 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

AstraZeneca PLC's third quarter result of 1.73 Billion USD for the item "Capital Expenditures" represents a decrease of -10.24 percent compared to it's second quarter result.

Also, AstraZeneca PLC's third quarter result of 1.73 Billion USD for the item "Capital Expenditures" represents an increase of 27.10 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 5.57 Billion USD for the item "Capital Expenditures" represents an increase of 7.07 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 21.76 percent compared to the value the year prior.
The 1 year change in percent is 21.76.
The 3 year change in percent is 103.77.
The 5 year change in percent is 128.12.
The 10 year change in percent is 104.74.

The Serie's long term average value is 2.76 Billion United States Dollars. It's latest available value, on 09/30/2025, is 101.75 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 06/30/2012, to it's latest available value, on 09/30/2025, is +404.34%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.